_id

690db436ccc777a4e85d0d37

Ticker

AXSM

Name

Axsome Therapeutics Inc

Exchange

NASDAQ

Address

One World Trade Center, New York, NY, United States, 10007

Country

USA

Sector

Healthcare

Industry

Biotechnology

Currency

USD

Website

https://www.axsome.com

Description

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Last Close

148.75

Volume

541258

Current Price

148.17

Change

-0.389915966386563

Last Updated

2025-11-28T12:38:38.267Z

Image

data:image/webp;base64,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

Ipo Date

2015-11-19T00:00:00.000Z

Market Cap

7611300352

Next Dividend Date

-

Dividend Frequency

-

Dividend Rate

-

Dividend Yield

0

Sentiment

0.7997588235294116

Sentiment Sources

17

Rating

4.7368

Target Price

179.741

Strong Buy

14

Buy

5

Hold

0

Sell

0

Strong Sell

0

Current Quarter

2025-09-30

Revenue

170992000

Cost Of Revenue

11912000

Gross Profit

159080000

Operating Expenses

205189000

Operating Income

-46109000

Interest Expense

1120000

Pretax Income

-47229000

Net Income

-47229000

Eps

-0.9441673799716048

Dividends Per Share

-

Shares Outstanding

50412640

Income Tax Expense

-

EBITDA

-44382000

Operating Margin

-26.965589033405074

Total Other Income Expense Net

-1120000

Cash

325272000

Short Term Investments

-

Receivables

196507000

Inventories

23774000

Total Current Assets

565342000

Property Plant Equipment

26654000

Total Assets

669250000

Payables

54227000

Short Term Debt

73233000

Long Term Debt

117642000

Total Liabilities

595523000

Equity

73727000

Depreciation

2411000

Change In Working Capital

8783000

Cash From Operations

1046000

Capital Expenditures

58000

Cash From Investing

-58000

Cash From Financing

21268000

Net Change In Cash

22256000

PE

-

PB

100.52948936848101

ROE

-64.05929984944457

ROA

-7.057004109077325

FCF

988000

Fcf Percent

0.005778048095817348

Piotroski FScore

2

Health Score

8

Deep Value Investing Score

3.5

Defensive Investing Score

5

Dividend Investing Score

2.5

Economic Moat Investing Score

4.8

Garp Investing Score

3.5

Growth Investing Score

3.5

Momentum Investing Score

2.5

Net Net Investing Score

2.5

Quality Investing Score

3

Value Investing Score

2

Quarters > 0 > quarter

2025-09-30

Quarters > 0 > income Statement > revenue

170992000

Quarters > 0 > income Statement > cost Of Revenue

11912000

Quarters > 0 > income Statement > gross Profit

159080000

Quarters > 0 > income Statement > operating Expenses

205189000

Quarters > 0 > income Statement > operating Income

-46109000

Quarters > 0 > income Statement > interest Expense

1120000

Quarters > 0 > income Statement > pretax Income

-47229000

Quarters > 0 > income Statement > net Income

-47229000

Quarters > 0 > income Statement > eps

-0.9441673799716048

Quarters > 0 > income Statement > dividends Per Share

-

Quarters > 0 > income Statement > shares Outstanding

50021851

Quarters > 0 > income Statement > income Tax Expense

-

Quarters > 0 > income Statement > EBITDA

-44382000

Quarters > 0 > income Statement > operating Margin

-26.965589033405074

Quarters > 0 > income Statement > total Other Income Expense Net

-1120000

Quarters > 0 > balance Sheet > cash

325272000

Quarters > 0 > balance Sheet > short Term Investments

-

Quarters > 0 > balance Sheet > receivables

196507000

Quarters > 0 > balance Sheet > inventories

23774000

Quarters > 0 > balance Sheet > total Current Assets

565342000

Quarters > 0 > balance Sheet > property Plant Equipment

26654000

Quarters > 0 > balance Sheet > total Assets

669250000

Quarters > 0 > balance Sheet > payables

54227000

Quarters > 0 > balance Sheet > short Term Debt

73233000

Quarters > 0 > balance Sheet > long Term Debt

117642000

Quarters > 0 > balance Sheet > total Liabilities

595523000

Quarters > 0 > balance Sheet > equity

73727000

Quarters > 0 > cash Flow > net Income

-47229000

Quarters > 0 > cash Flow > depreciation

2411000

Quarters > 0 > cash Flow > change In Working Capital

8783000

Quarters > 0 > cash Flow > cash From Operations

1046000

Quarters > 0 > cash Flow > capital Expenditures

58000

Quarters > 0 > cash Flow > cash From Investing

-58000

Quarters > 0 > cash Flow > cash From Financing

21268000

Quarters > 0 > cash Flow > net Change In Cash

22256000

Quarters > 0 > ratios > PE

-0.9441673799716048

Quarters > 0 > ratios > PB

100.52948936848101

Quarters > 0 > ratios > ROE

-64.05929984944457

Quarters > 0 > ratios > ROA

-7.057004109077325

Quarters > 0 > ratios > FCF

988000

Quarters > 0 > ratios > Piotroski FScore

2

Quarters > 0 > ratios > fcf Percent

0.005778048095817348

Quarters > 0 > health Score

8

Quarters > 1 > quarter

2025-06-30

Quarters > 1 > income Statement > revenue

150042000

Quarters > 1 > income Statement > cost Of Revenue

13448000

Quarters > 1 > income Statement > gross Profit

136594000

Quarters > 1 > income Statement > operating Expenses

173308000

Quarters > 1 > income Statement > operating Income

-36714000

Quarters > 1 > income Statement > interest Expense

1834000

Quarters > 1 > income Statement > pretax Income

-48933000

Quarters > 1 > income Statement > net Income

-47973000

Quarters > 1 > income Statement > eps

-0.9702884187532866

Quarters > 1 > income Statement > dividends Per Share

-

Quarters > 1 > income Statement > shares Outstanding

49442000

Quarters > 1 > income Statement > income Tax Expense

-960000

Quarters > 1 > income Statement > EBITDA

-42570000

Quarters > 1 > income Statement > operating Margin

-24.469148638381252

Quarters > 1 > income Statement > total Other Income Expense Net

-12219000

Quarters > 1 > balance Sheet > cash

303016000

Quarters > 1 > balance Sheet > short Term Investments

-

Quarters > 1 > balance Sheet > receivables

198825000

Quarters > 1 > balance Sheet > inventories

18441000

Quarters > 1 > balance Sheet > total Current Assets

536620000

Quarters > 1 > balance Sheet > property Plant Equipment

23139000

Quarters > 1 > balance Sheet > total Assets

639785000

Quarters > 1 > balance Sheet > payables

91628000

Quarters > 1 > balance Sheet > short Term Debt

72351000

Quarters > 1 > balance Sheet > long Term Debt

117540000

Quarters > 1 > balance Sheet > total Liabilities

566710000

Quarters > 1 > balance Sheet > equity

73075000

Quarters > 1 > cash Flow > net Income

-47973000

Quarters > 1 > cash Flow > depreciation

1709000

Quarters > 1 > cash Flow > change In Working Capital

-14331000

Quarters > 1 > cash Flow > cash From Operations

-32423000

Quarters > 1 > cash Flow > capital Expenditures

13000

Quarters > 1 > cash Flow > cash From Investing

-13000

Quarters > 1 > cash Flow > cash From Financing

34542000

Quarters > 1 > cash Flow > net Change In Cash

2106000

Quarters > 1 > ratios > PE

-0.9702884187532866

Quarters > 1 > ratios > PB

100.25071693465615

Quarters > 1 > ratios > ROE

-65.64899076291482

Quarters > 1 > ratios > ROA

-7.498300210226873

Quarters > 1 > ratios > FCF

-32436000

Quarters > 1 > ratios > Piotroski FScore

1

Quarters > 1 > ratios > fcf Percent

-0.21617946974847044

Quarters > 1 > health Score

9

Quarters > 2 > quarter

2025-03-31

Quarters > 2 > income Statement > revenue

121463000

Quarters > 2 > income Statement > cost Of Revenue

9789000

Quarters > 2 > income Statement > gross Profit

111674000

Quarters > 2 > income Statement > operating Expenses

168656000

Quarters > 2 > income Statement > operating Income

-56982000

Quarters > 2 > income Statement > interest Expense

2431000

Quarters > 2 > income Statement > pretax Income

-59413000

Quarters > 2 > income Statement > net Income

-59413000

Quarters > 2 > income Statement > eps

-1.2157066939454664

Quarters > 2 > income Statement > dividends Per Share

-

Quarters > 2 > income Statement > shares Outstanding

48871163

Quarters > 2 > income Statement > income Tax Expense

-

Quarters > 2 > income Statement > EBITDA

-54849000

Quarters > 2 > income Statement > operating Margin

-46.913051711220696

Quarters > 2 > income Statement > total Other Income Expense Net

-2431000

Quarters > 2 > balance Sheet > cash

300910000

Quarters > 2 > balance Sheet > short Term Investments

-

Quarters > 2 > balance Sheet > receivables

161398000

Quarters > 2 > balance Sheet > inventories

16319000

Quarters > 2 > balance Sheet > total Current Assets

494634000

Quarters > 2 > balance Sheet > property Plant Equipment

24067000

Quarters > 2 > balance Sheet > total Assets

596671000

Quarters > 2 > balance Sheet > payables

85659000

Quarters > 2 > balance Sheet > short Term Debt

2270000

Quarters > 2 > balance Sheet > long Term Debt

181377000

Quarters > 2 > balance Sheet > total Liabilities

543466000

Quarters > 2 > balance Sheet > equity

53205000

Quarters > 2 > cash Flow > net Income

-59413000

Quarters > 2 > cash Flow > depreciation

1721000

Quarters > 2 > cash Flow > change In Working Capital

-10149000

Quarters > 2 > cash Flow > cash From Operations

-43375000

Quarters > 2 > cash Flow > capital Expenditures

338000

Quarters > 2 > cash Flow > cash From Investing

-338000

Quarters > 2 > cash Flow > cash From Financing

29270000

Quarters > 2 > cash Flow > net Change In Cash

-14443000

Quarters > 2 > ratios > PE

-1.2157066939454664

Quarters > 2 > ratios > PB

136.10074657851703

Quarters > 2 > ratios > ROE

-111.66807630861761

Quarters > 2 > ratios > ROA

-9.957413717107084

Quarters > 2 > ratios > FCF

-43713000

Quarters > 2 > ratios > Piotroski FScore

1

Quarters > 2 > ratios > fcf Percent

-0.3598873731095066

Quarters > 2 > health Score

9

Quarters > 3 > quarter

2024-12-31

Quarters > 3 > income Statement > revenue

118766000

Quarters > 3 > income Statement > cost Of Revenue

10514000

Quarters > 3 > income Statement > gross Profit

108252000

Quarters > 3 > income Statement > operating Expenses

180869000

Quarters > 3 > income Statement > operating Income

-72617000

Quarters > 3 > income Statement > interest Expense

2210000

Quarters > 3 > income Statement > pretax Income

-74827000

Quarters > 3 > income Statement > net Income

-74912000

Quarters > 3 > income Statement > eps

-1.5432439250169518

Quarters > 3 > income Statement > dividends Per Share

-

Quarters > 3 > income Statement > shares Outstanding

48541905

Quarters > 3 > income Statement > income Tax Expense

85000

Quarters > 3 > income Statement > EBITDA

-70544000

Quarters > 3 > income Statement > operating Margin

-61.142919690820605

Quarters > 3 > income Statement > total Other Income Expense Net

-2210000

Quarters > 3 > balance Sheet > cash

315353000

Quarters > 3 > balance Sheet > short Term Investments

-

Quarters > 3 > balance Sheet > receivables

142001000

Quarters > 3 > balance Sheet > inventories

15732000

Quarters > 3 > balance Sheet > total Current Assets

485064000

Quarters > 3 > balance Sheet > property Plant Equipment

5967000

Quarters > 3 > balance Sheet > total Assets

568498000

Quarters > 3 > balance Sheet > payables

71997000

Quarters > 3 > balance Sheet > short Term Debt

3256000

Quarters > 3 > balance Sheet > long Term Debt

180710000

Quarters > 3 > balance Sheet > total Liabilities

511483000

Quarters > 3 > balance Sheet > equity

57015000

Quarters > 3 > cash Flow > net Income

-74912000

Quarters > 3 > cash Flow > depreciation

2073000

Quarters > 3 > cash Flow > change In Working Capital

12799000

Quarters > 3 > cash Flow > cash From Operations

-26202000

Quarters > 3 > cash Flow > capital Expenditures

30000

Quarters > 3 > cash Flow > cash From Investing

-30000

Quarters > 3 > cash Flow > cash From Financing

14244000

Quarters > 3 > cash Flow > net Change In Cash

-11988000

Quarters > 3 > ratios > PE

-1.5432439250169518

Quarters > 3 > ratios > PB

126.15020720599841

Quarters > 3 > ratios > ROE

-131.38998509164256

Quarters > 3 > ratios > ROA

-13.177179163339185

Quarters > 3 > ratios > FCF

-26232000

Quarters > 3 > ratios > Piotroski FScore

1

Quarters > 3 > ratios > fcf Percent

-0.22087129313103077

Quarters > 3 > health Score

9

Valuation > metrics > PE

-0.9441673799716048

Valuation > metrics > PB

100.52948936848101

Valuation > final Score

20

Valuation > verdict

3251.0% Overvalued

Profitability > metrics > ROE

-64.05929984944457

Profitability > metrics > ROA

-8.354058251465485

Profitability > metrics > Net Margin

-0.2762059043697951

Profitability > final Score

0

Profitability > verdict

Weak

Risk > metrics > Debt Equity

8.077407191395283

Risk > metrics > Interest Coverage

-41.16875

Risk > final Score

-159

Risk > verdict

High

Liquidity > metrics > Current Ratio

4.435446414561431

Liquidity > metrics > Quick Ratio

4.248925152989173

Liquidity > final Score

100

Liquidity > verdict

Great

Prev Valuations > 0

20

Prev Valuations > 1

20

Prev Valuations > 2

20

Prev Profitabilities > 0

0

Prev Profitabilities > 1

0

Prev Profitabilities > 2

0

Prev Risks > 0

-74

Prev Risks > 1

-88

Prev Risks > 2

-125

Prev Liquidities > 0

100

Prev Liquidities > 1

100

Prev Liquidities > 2

100

Updated At

2025-12-14T00:15:31.723Z